TNF Blockers News and Research

RSS

Thymoquinone inhibits the development of pancreatic cancer

An herb recently found to kill pancreatic cancer cells also appears to inhibit development of pancreatic cancer as a result of its anti-inflammatory properties, according to researchers from the Kimmel Cancer Center at Jefferson.

20 Apr 2009

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).

13 Apr 2009

Vitamin D deficiency is associated with inflammation in healthy women

According to a recent study in the Archives of Internal Medicine, 75 percent of Americans do not get enough Vitamin D.

9 Apr 2009

Trial of new biologic agent to treat psoriatic arthritis

Psoriatic arthritis affects about 11 percent of patients with psoriasis.

8 Apr 2009

Paradigm shift in the regulation of immune response

Over the past decade various pieces of the puzzle how signal transmission controls immunity have been coming together.

20 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Mice with "superhealing" powers provide clues to treating arthritis caused by traumatic injury

A strain of laboratory mice that has "superhealing" powers has been found to resist inflammation after a knee injury, and also to avoid developing arthritis at the injury site in the long term, according to researchers at Duke University Medical Center.

22 Feb 2009

New approaches to prevent transplant rejection

To prevent the rejection of newly transplanted organs and cells, patients must take medicines that weaken their entire immune systems.

15 Feb 2009

Gene therapy used to treat periodontal disease

Scientists at the University of Michigan have shown that gene therapy can be used to successfully stop the development of periodontal disease, the leading cause of tooth loss in adults.

12 Dec 2008

Rituxan in combination with chemo improves survival in chronic lymphocytic leukemia

Genentech, Inc. and Biogen Idec have announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.

8 Dec 2008

Vitamin E supplementation may reduce inflammation in the brain

With up to half of a person's body mass consisting of skeletal muscle, chronic inflammation of those muscles - which include those found in the limbs - can result in significant physical impairment.

5 Dec 2008

Better management of arthritis more important than new drugs

Although there has been an increase in the number of new arthritis treatments in recent years, the best results will come from more effective use of the drugs we have.

26 Nov 2008

MorphoSys granted U.S. patent on antibodies against GM-CSF to treat inflammatory disorders

MorphoSys AG and the University of Melbourne announced today that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF.

25 Nov 2008

Soviet-developed immune formula boosts immune activity

A recent study on an American-made, Soviet-developed immune formula shows the product has a significant effect on immune function.

19 Nov 2008

Musculoskeletal Center wins $2.2 million to study biologics safety

The UAB Center for Education and Research on Therapeutics has won a $2.2 million federal grant to study the risks and benefits of a class of drugs called ‘biologics' -- genetically engineered agents targeting the immune system of patients with rheumatoid arthritis, Crohn's disease, psoriasis and other autoimmune disorders.

18 Nov 2008

Adalimumab therapy may reduce health-care costs for Crohn's disease patients

Inflammatory bowel disease (IBD) is a term that refers to both ulcerative colitis (UC) and Crohn's disease (CD).

12 Nov 2008

Cimzia study shows reduction of symptoms and progression of rheumatoid arthritis

UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.

31 Oct 2008

New drug combo stops rheumatoid arthritis in its tracks

The trial of a new drug for rheumatoid arthritis (RA) has revealed that an injection once a month could stop the disease progressing.

28 Oct 2008

First-ever international guidelines for the treatment of psoriatic arthritis

Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.

26 Oct 2008

FDA grants orphan drug status to Reata's pancreatic cancer drug

Reata Pharmaceuticals, Inc. has announced that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.

16 Oct 2008